Xcout IntelBriaCell Therapeutics Corp. competitors & alternatives
The 12 closest competitors and alternatives to BriaCell Therapeutics Corp. among biotech companies — ranked by similarity to what BriaCell Therapeutics Corp. actually does, not by market-cap band.
Subscribe to see BriaCell Therapeutics Corp.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.
BriaCell Therapeutics Corp. at a glance
BriaCell Therapeutics Corp. is a biotech company headquartered in West Vancouver, Canada. It is publicly listed (BCTX) with a market capitalisation of $6.7M. Xcout tracks 13 named people at BriaCell Therapeutics Corp., including William V. Williams (Chief Executive Officer, President & Director).
BriaCell Therapeutics Corp. leadership
- William V. WilliamsChief Executive Officer, President & Director
- Gadi LevinChief Financial Officer & Corporate Secretary
- Giuseppe Del PrioreChief Medical Officer
- Miguel A. Lopez-LagoChief Scientific Officer
- Jamieson BondarenkoChairman of the Board
- Charles Louis Wiseman FACPFounder, Principal Research Advisor & Member of Scientific Advisory Board
7 more named people on record for BriaCell Therapeutics Corp., with roles, board committees and tenure — see the full roster →
Top 12 BriaCell Therapeutics Corp. competitors
Ranked by semantic similarity — how close each company is to BriaCell Therapeutics Corp. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Life Sciences
ImStar Therapeutics Inc. is a biotechnology company headquartered in Vancouver, British Columbia, focused on breakthrough science and drug discovery.
Biotechnology
Reverb Therapeutics is a biotechnology research company headquartered in Vancouver, British Columbia. The company focuses on cancer therapeutics by developing its proprietary Amplify-R platform designed to intelligently adjust and tune the body's natural immune system.
Biotechnology
BriSTAR Immunotech Limited is a clinical-stage cell therapy company actively developing universal cell therapies with a differentiated product pipeline and offices in Beijing and Suzhou.
Biotechnology
Imvax, Inc. is a clinical-stage biotechnology company headquartered in Philadelphia, Pennsylvania, focused on developing personalized, whole-cell immunotherapies for the treatment of various cancers.
Biotechnology
Arcellx, Inc. is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, dedicated to developing innovative immunotherapies and cell therapies for cancer patients.
Biotechnology
BrainChild Bio is a clinical-stage biotechnology company that develops CAR-T cell therapies to treat tumors in the central nervous system (CNS). The company prioritizes pediatric patients with brain tumors while also extending its technology platform to address adult indications such as glioblastoma and brain metastases.
Biotechnology
ImmuXell Biotechnology is a clinical-stage biopharmaceutical innovation company headquartered in Shanghai, China. Founded in 2021, the company focuses on developing novel immune cell therapies targeted at treating solid tumor cancers.
Biotechnology
ME Therapeutics Holdings Inc. is a clinical-stage biotechnology company that discovers and develops immuno-oncology therapeutics designed to reprogram immune cells in vivo. Its pipeline aims to activate the body's immune system to recognize and fight cancer cells.
Similar biotech company
Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.
Similar biotech company
Lytix Biopharma is a clinical-stage biotechnology company developing oncolytic molecule therapies to treat superficial and deep-seated tumors. The company focuses on the neoadjuvant setting, providing first-in-class immunotherapies designed to destroy cancer cell membranes and stimulate a broad immune response.
Biotechnology
Mesentech Inc. is an active for-profit biotechnology company focused on drug pipelines, therapeutic areas, and proprietary technology platforms. Headquartered in Vancouver, British Columbia, Canada, the company operates with a small team specializing in clinical research and development.
Similar biotech company
BioVaxys Technology Corp. (BVAXF) is a clinical-stage biotechnology company primarily engaged in the development of innovative vaccine platforms targeting both antiviral diseases and various forms of cancer. Its product pipeline features several key candidates, including two SARS-CoV-2 vaccines: BVX-0320, a monovalent version, and BVX-0121, a multivalent option. In the oncology space, BioVaxys is advancing BVX-0918A, a haptenized tumor cell vaccine designed for ovarian cancer, and BVX-0918C, aimed at cervical cancer. The company also has programs addressing Human Papillomavirus (HPV), such as Papilocare for HPV-dependent cervical lesions and the BVX-0204 HPV viral vaccine. Furthermore, BioVaxys offers CoviDTH, an immunodiagnostic tool developed to detect immune system responses in individuals previously exposed to SARS-CoV-2. To support its development initiatives, BioVaxys has established several strategic collaborations. It holds a bioproduction agreement with WuXi Biologics Limited for the manufacturing of SARS-CoV-2 s-proteins, crucial components for BVX-0320 and CoviDTH. The company also has a research collaboration for BVX-0320 with The Ohio State University, Wexner School of Medicine. Additionally, Bioanalytical Systems, Inc. is conducting preclinical toxicology studies for BioVaxys' CoviDTH immunodiagnostic under a separate agreement. The company's operations are headquartered in Vancouver, Canada.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of BriaCell Therapeutics Corp. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for BriaCell Therapeutics Corp.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →